1. Indications:

Brutini (Ibrutinib) 140 mg is indicated for the treatment of various hematologic malignancies, including:

• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)
• Mantle cell lymphoma (MCL)
• Waldenström’s macroglobulinemia (WM)
• Marginal zone lymphoma (MZL)
• Chronic graft versus host disease (cGVHD)

2. Pharmacology:

Brutini (Ibrutinib) 140 mg exerts its pharmacological effects by irreversibly inhibiting Bruton’s tyrosine kinase (BTK), a key enzyme involved in B-cell receptor signaling pathways. By disrupting these signaling pathways, Brutini suppresses B-cell survival, proliferation, and trafficking, leading to apoptosis (programmed cell death) of cancerous B-cells and inhibiting tumor growth.

3. Dosage and Administration:

The dosage of Brutini (Ibrutinib) 140 mg may vary depending on the type of cancer being treated and individual patient characteristics. Typically, the recommended dose is 140 mg taken orally once daily with a glass of water, preferably at the same time each day. Patients should follow the prescribed dosage regimen and consult their healthcare provider for any adjustments.

4. Interaction:

Brutini (Ibrutinib) 140 mg may interact with other medications, including:

• Anticoagulants: Concurrent use may increase the risk of bleeding complications.
• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Brutini.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to minimize the risk of potential interactions.

5. Side Effects:

Common side effects associated with Brutini (Ibrutinib) 140 mg may include:

• Diarrhea
• Fatigue
• Nausea
• Rash
• Bruising
• Muscle pain

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Brutini (Ibrutinib) 140 mg, patients should be aware of the following precautions:

• Brutini may increase the risk of bleeding, so caution is advised in patients with a history of bleeding disorders or concurrent use of anticoagulants.
• Patients should undergo regular monitoring of blood counts and liver function tests during treatment with Brutini.
• Pregnant or breastfeeding women should avoid Brutini due to the potential risk of fetal harm.

7. Overdose Effects:

In case of overdose with Brutini (Ibrutinib) 140 mg, symptoms may include:

• Increased risk of bleeding
• Gastrointestinal disturbances
• Fatigue
• Rash

Patients experiencing signs or symptoms of overdose should seek immediate medical attention or contact a poison control center for assistance.